Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
315 Leser
Artikel bewerten:
(1)

Medical Microinstruments, Inc. (MMI): Medical Microinstruments Introduces Even Smaller Robotic Instruments to Address Complex Supermicrosurgery

First Procedures with New Supermicro Instruments Performed in Europe

PISA, Italy, Sept. 7, 2022 /PRNewswire/ -- Medical Microinstruments, Inc. (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its new Supermicro NanoWrist instruments for use with the Symani Surgical System, developed specifically to address the challenges of microsurgery. The new supermicro needle holder and dilator were recently used in clinical procedures in Zürich, Florence, and Salzburg, with successful patient outcomes.

Medical Microinstruments, Inc. (MMI) Logo

Simon Enzinger, MD, DDS, surgeon at the Department of Oral and Maxillofacial Surgery at the University Hospital Salzburg, used the new instruments on a procedure called a partial glossectomy, where he raised a lateral arm free flap to replace a large section of a patient's tongue which required removal due to cancer. To return blood flow to the transferred tissue, Dr. Enzinger needed to connect the branch of the radial collateral artery to a side brand of the superior thyroid artery that was only 0.8mm in diameter and in a difficult location to access.

"We've already seen the benefits of Symani and the NanoWrist instruments in improving dexterity and control," said Dr. Enzinger. "The new supermicro instrument tips are even smaller and more refined, making it significantly easier to precisely connect vessels under one millimeter in diameter. I believe this will expand the ability to use perforator-to-perforator flaps, which makes free-flap surgeries shorter and less invasive."

MMI's Supermicro NanoWrist instruments are commercially available in the European Union (EU). The tips of the new instruments are half the width of MMI's standard microinstruments with a tapered design optimized to connect vessels under one millimeter in diameter and delicately hold 10-0 to 12-0 sutures.

Microsurgery is the manipulation or suturing of very small anatomy such as arteries, veins, ducts, or nerves. These procedures require high visual magnification and specialized precision instruments as well as advanced fine motor skills. Supermicrosurgery is microsurgery on an even smaller scale. Symani has enabled lymphatic surgery by adding precision that not every surgeon can achieve, even with extensive training, when manually suturing extremely small vessels.

"The launch of our new supermicro instruments is a significant milestone as we push the boundaries of robotic surgery to address even smaller vessels that few surgeons are able to connect by hand," said Mark Toland, CEO of MMI. "We're excited that our innovative solutions will allow more surgeons to perform microsurgical techniques and help expand patient access to supermicrosurgeries for chronic illnesses like lymphedema, a burdensome condition that affects 250 million people around the world."

About Medical Microinstruments, Inc.

Medical Microinstruments, Inc. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world's smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of supermicrosurgery. MMI is backed by international medtech investors including Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital and Sambatech.

Logo - https://mma.prnewswire.com/media/1308712/MMI_SpA_Logo.jpg

© 2022 PR Newswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.